dc.contributor.author |
Duque, Natalia |
dc.contributor.author |
Artime, Esther |
dc.contributor.author |
Romera, Irene |
dc.contributor.author |
Lebrec, Jeremie |
dc.contributor.author |
Díaz, Silvia |
dc.contributor.author |
Rubio, Miriam |
dc.contributor.author |
Sicras Mainar, Antoni |
dc.contributor.author |
Carretero Anibarro, Enrique |
dc.contributor.author |
Mundet-Tudurí, Xavier |
dc.contributor.author |
Gorgojo Martínez, Juan José |
dc.contributor.author |
Reviriego, Jesús |
dc.date |
2021 |
dc.identifier |
https://ddd.uab.cat/record/248431 |
dc.identifier |
urn:10.1007/s12325-021-01773-z |
dc.identifier |
urn:oai:ddd.uab.cat:248431 |
dc.identifier |
urn:pmcid:PMC8280027 |
dc.identifier |
urn:pmc-uid:8280027 |
dc.identifier |
urn:pmid:34052987 |
dc.identifier |
urn:articleid:18658652v38p3857 |
dc.identifier |
urn:oai:pubmedcentral.nih.gov:8280027 |
dc.identifier |
urn:oai:egreta.uab.cat:publications/fb2db5a6-ddaf-4380-8af0-aa9f8c77f542 |
dc.identifier |
urn:scopus_id:85107032650 |
dc.format |
application/pdf |
dc.language |
eng |
dc.publisher |
|
dc.relation |
Advances in Therapy ; Vol. 38 (may 2021), p. 3857-3871 |
dc.rights |
open access |
dc.rights |
Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. |
dc.rights |
https://creativecommons.org/licenses/by-nc/4.0/ |
dc.subject |
Cost |
dc.subject |
Dose |
dc.subject |
Glycaemic control |
dc.subject |
Insulin glargine |
dc.subject |
Real-world evidence |
dc.subject |
Type 2 diabetes mellitus |
dc.subject |
U100 |
dc.subject |
U300 |
dc.title |
Real-World Use of Insulin Glargine U100 and U300 in Insulin-Naïve Patients with Type 2 Diabetes Mellitus : DosInGlar Study |
dc.type |
Article |
dc.description.abstract |
In the EDITION clinical trial programme, patients with type 2 diabetes mellitus (T2DM) receiving insulin glargine (IGlar) U300 required 10-15% more insulin than those receiving IGlar U100. This study sought to determine whether this difference was apparent in real-world practice. In this observational, retrospective cohort study, electronic medical records in the Big-Pac® database (Real Life Data) relating to adult insulin-naïve patients with T2DM who initiated IGlar U100 or U300 treatment in Spain in 2016-2017 and remained on treatment for 18 months were selected. IGlar U100- and U300-treated patients were matched 1:1 (propensity score matching). The primary analysis compared changes from baseline in mean daily IGlar dose (U and U/kg) at 6 (± 2), 12 (± 2) and 18 (± 2) months between cohorts (paired t tests). Changes in glycated haemoglobin (HbA1c) and weight were analysed descriptively. The IGlar U100 and U300 cohorts included 556 matched pairs (46.9% female) with the following mean (standard deviation) values at baseline, respectively: age 63.6 (12.8) versus 63.7 (11.9) years; years since diagnosis 9.5 (1.4) versus 9.5 (1.3); HbA1c 8.8 (1.3) versus 8.7 (1.5) %; weight 84.6 (16.9) versus 84.7 (17.1) kg. Mean IGlar dose at baseline was 0.19 U/kg/day (both cohorts). Patients receiving IGlar U300 showed a greater increase from baseline in IGlar dose at 6, 12 and 18 months [mean dose (U/kg/day) 5.1%, 10.3% and 12.8% greater, respectively, in IGlar U300-treated patients]. Mean HbA1c was 8.1% in both cohorts at 18 months. Mean (SD) weight at 18 months with IGlar U100 and IGlar300 was 86.8 (17.0) kg and 85.0 (17.1) kg, respectively. In real-world practice, insulin dose was significantly higher in IGlar U300-treated than U100-treated patients at 6, 12 and 18 months, with similar reductions in HbA1c. At equal IGlar price/unit in Spain, the increased dose requirements of IGlar U300 would result in higher costs. The online version contains supplementary material. |